This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 May;7(5):328-329.

doi: 10.1016/S2213-8587(19)30069-5. Epub 2019 Mar 1.

Rational combination therapy for type 2 diabetes

Stefano Del Prato¹

Affiliations

PMID: 30833171
DOI: 10.1016/S2213-8587(19)30069-5

Comment

Rational combination therapy for type 2 diabetes

Stefano Del Prato. Lancet Diabetes Endocrinol. 2019 May.

. 2019 May;7(5):328-329.

doi: 10.1016/S2213-8587(19)30069-5. Epub 2019 Mar 1.

Author

Stefano Del Prato¹

Affiliation

¹ Department of Clinical & Experimental Medicine, University of Pisa, Pisa 56124, Italy. Electronic address: stefano.delprato@med.unipi.it.

PMID: 30833171
DOI: 10.1016/S2213-8587(19)30069-5

No abstract available

PubMed Disclaimer

Comment on

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, Thrasher J, Woo V, Philis-Tsimikas A. Zinman B, et al. Lancet Diabetes Endocrinol. 2019 May;7(5):356-367. doi: 10.1016/S2213-8587(19)30066-X. Epub 2019 Mar 1. Lancet Diabetes Endocrinol. 2019. PMID: 30833170 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information